Analyst Profile

Followed by 256 followers
.
Paul Choi

Paul Choi

Goldman Sachs
Wall Street Analyst
#1,733 out of 8,087 Wall Street Analysts
#3,587 out of 24,283 experts

Success Rate

50%
59 out of 117 transactions made a profit

Average Return

+7.50%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Paul Choi's trades since 2017 and holding each position for 1 Year would result in 50.43% of your transactions generating a profit, with an average return of 7.5% per rating.

Stock Rating Distribution

220Ratings
43.18% Buy
40.45% Hold
16.36% Sell
Distribution of Paul Choi's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Myovant Sciences
(MYOV)
Rating:Buy
Date:Oct 25, 2019 - Oct 25, 2020
Return:+252.30%
The most profitable rating made by Paul Choi

Paul Choi's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
Eli Lilly & Co
Apr 07, 2017
Buy
Reiterated
$90.00
(-75.54% Downside)
1Ratings
0%
-7.50%
Incyte
Nov 01, 2017
Buy
Reiterated
$165.00
(96.55% Upside)
2Ratings
0%
-45.45%
TSRO
Tesaro
Feb 28, 2018
Hold
Reiterated
2Ratings
0.00%
LOXO
Loxo Oncology
Sep 17, 2018
Hold
Initiated
1Ratings
0.00%
MDCO
Medicines Co
Apr 26, 2019
Buy
Upgraded
2Ratings
100%
+168.80%
TPTX
Turning Point Therapeutics
May 13, 2019
Buy
Initiated
$50.00
(-34.22% Downside)
1Ratings
100%
+93.90%
~ARRY
Array Biopharma
Jun 17, 2019
Hold
Reiterated
2Ratings
0.00%
AIMT
Aimmune Therapeutics
Mar 12, 2020
Hold
Reiterated
4Ratings
0.00%
Nektar Therapeutics
Mar 30, 2020
Hold
Upgraded
$20.00
(586.11% Upside)
5Ratings
50%
-6.50%
XLRN
Acceleron Pharma
Apr 06, 2020
Sell
Downgraded
4Ratings
0%
-58.90%
List of latest recommendations made by Paul Choi. Click to expand and see Paul Choi's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >